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Abstract
Parkinson’s Disease is a neurological condition distinguished by characteristic
motor symptoms including tremor and slowness of movement. To enable the
frequent assessment of PD patients, this paper introduces the cloudUPDRS app,
a Class I medical device that is an active transient non-invasive instrument, cer-
tified by the Medicines and Healthcare products Regulatory Agency in the UK.
The app follows closely Part III of the Unified Parkinson’s Disease Rating Scale
which is the most commonly used protocol in the clinical study of PD; can be
used by patients and their carers at home or in the community unsupervised;
and, requires the user to perform a sequence of iterated movements which are
recorded by the phone sensors. The cloudUPDRS system addresses two key
challenges towards meeting essential consistency and efficiency requirements,
namely: (i) How to ensure high-quality data collection especially considering
the unsupervised nature of the test, in particular, how to achieve firm user ad-
herence to the prescribed movements; and (ii) How to reduce test duration from
approximately 25 minutes typically required by an experienced patient, to below
4 minutes, a threshold identified as critical to obtain significant improvements
in clinical compliance. To address the former, we combine a bespoke design of
the user experience tailored so as to constrain context, with a deep learning ap-
proach based on Recurrent Convolutional Neural Networks, to identify failures
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to follow the movement protocol. We address the latter by developing a ma-
chine learning approach to personalize assessments by selecting those elements
of the test that most closely match individual symptom profiles and thus offer
the highest inferential power, hence closely estimating the patent’s overall score.
1. Introduction
Parkinson’s Disease (PD) is a degenerative neurological condition associ-
ated with a wide spectrum of motor and cognitive symptoms including tremor,
slowness of movement and freezing, muscular stiffness, poor postural stability,
sleep-related difficulties, depression and psychosis [24]. The underlying cause of
PD is the degeneration of the so-called dopaminergic neurons, that is, a small
group of neurons located in the mid-brain that are the main source of dopamine
in the human central nervous system [11]. Dopaminergic neurons play a cru-
cial role in the control of many brain functions including voluntary movement,
mood, reward, addiction, stress and in particular, in the reward system that
controls learning. Although the cause for the loss of these neurons is unknown,
their selective degeneration leads to PD and its distinctive presentation.
Care for patients with PD involves the management of both motor and non-
motor symptoms as well as palliative care. Since there is no cure, symptom
management is a life-long process that affects not only the patients but also
their families and carers. Clinical care pathways include pharmacological treat-
ment corresponding to the exact stage of the disease, physiotherapy, and surgery
[45]. As a result of medication with L-Dopa, a key element of the typical phar-
macological regime for PD, patients are expected to develop side effects such
as dyskinesias [55]. Since symptoms vary greatly independently of treatment
and PD progresses at different rates in different individuals, treatment requires
regular clinical monitoring and medication adjustment.
There are over 130,000 people with Parkinson’s in the UK and as many as
one million in the US, each individual seen by a specialist doctor or nurse only
once or twice a year, allowing only brief and intermittent assessment of the
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wide range of their motor and non-motor symptoms [48]. This is due to the
fact that the application of clinical measures of disease progression is laborious
and as a consequence costly, because they require the direct involvement of a
member of the clinical team. Moreover, although clinical measure protocols
are detailed and formally structured they nevertheless represent assesement at
relatively coarse-grain granularity, typically not involving the use of specialised
measurement instrumentation. Despite generally good internal consistency in
the application of these measures, they still depend on subjective estimations
of patient performance by the clinician. Collectively, these factors restrict op-
portunities to precisely quantify PD progression and the effectiveness of patient
stratification: the limited availability of data concerning individual variability
and actual symptom trends limits opportunities to adapt care to the needs of a
particular individual at a specific time.
To address this challenge we developed cloudUPDRS, the first smartphone
app to achieve certification as a Class I medical device by the Medicines &
Healthcare products Regulatory Agency in the UK for the clinical assessment
of the motor symptoms of Parkinson’s. cloudUPDRS augments standard clini-
cal care pathways by enabling daily assessments which lead to (i) more consis-
tent and reliable care, (ii) early identification of problems such as medication
side-effects, thus enabling earlier intervention, (iii) monitoring of individualised
patient trends leading to more effective patient stratification, and (v) enabling
patients to take ownership of their own care through non-pharmacological mea-
sures such as improved nutrition and physical therapy.
The cloudUPDRS system is based on the Universal Parkinson’s Disease Rat-
ing Scale [18] and the Parkinson’s Disease Questionnaire [25], and incorporates
a cloud-based Big Data management and analytics service to generate objective
and reliable assessments of motor performance. Patients use the app at home
to record sensor measurements while performing a series of simple actions with
each limb, such as tapping the screen to assess bradykinesia and holding the
phone on their knee to assess resting tremor. The data captured by the phone
is then used to calculate the clinical UPDRS score through the application of
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a biomedical signal processing pipeline. Additional longitudinal analytics are
performed subsequently to enable trend analysis and patient stratification.
In this paper, we extend the work discussed in [57] to present two distinctive
features of cloudUPDRS developed to address specific challenges related with
care for PD patients, namely:
• A deep learning technique employing Recurrent Convolutional Neural Net-
works applied to sensor observations so as to assess compliance with the
actions dictated by the UPDRS protocol. Combined with a bespoke user
experience facilitated by the app, this technique can replace expert super-
vision while maintaining high-quality data collection.
• Personalised tests reducing the time required to carry out an assessment to
less than 4 minutes. These so-called quick tests are created using machine
learning to select a subset of UPDRS observations that closely estimate
the motor performance of a particular patient.
In the following section we review research related to this work and in Section
3 summarise the state-of-the-art in current clinical practice for the assesmenet
of PD. We proceed to report on key factors for patient compliance identified
through user research in Section 4. We present the cloudUPDRS system in
Section 5 and in Section 6 we report on how the process of certification as a
medical device affetcs software development. We then present the details of the
two techniques identified above in Sections 7 and 8 correspondingly.
2. Related Work
During tha past two years, several smartphone apps have been developed to
address the different needs of PD patients including: the mPower app (http:
//parkinsonmpower.org/) developed for iOS by Apple (http://researchkit.
org/) and Sage Bionetworks in the US [53]; the uMotif app developed with NHS
SBRI Healthcare funding in the UK; the Wearable Companion app developed
by the M.J. Fox Foundation and Intel; the mHP app for Parkinsons developed
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by myHealthPal; PD Dr by the Muhammad Ali Parkinson Center at the Bar-
row Neurological Institute inthe US [47]; the Verily app in collaboration with
ParkinsonNet in Holland; and several others. In this list we do not include
apps that rely solely on self-reporting using diaries as they offer no direct way
to conduct objective measurements of performance. In contrast to standard
clinical practice, these apps follow a High-Frequency pattern of assessment; this
terminology reflects the fact that the apps are able to carry out measurements
of most elements of motor and cognitive performance of PD patients multiple
times per day or even continuously when wearables are used in addition to a
smartphone [31]. Nevertheless, none of the above apps has been certified as a
medical device and their stated purpose is to assist research into PD or support
self-quantification as a lifestyle choice for patients. Data collected by these apps
cannot be used for clinical purposes.
In particular, the two major projects by the M. J. Fox Foundation listed
above explore the diversity of PD motor symptoms within a large population
sample. The first employs the mPower app and aims to develop a large data
set of motor performance observations, which can be used as a benchmark for
the experimental evaluation of algorithms providing PD diagnosis. Clearly, long-
term research in PD necessitates the development of such open data sets however
the approach adopted depends solely on self-reporting to discriminate between
patient and non-patient data and confirm compliance with the prescribed data
collection protocol, and as such it is limited by the fact that these cannot be
verified objectively.
The second M.J. Fox Foundation project is carried out in collaboration with
Intel and The Grove Foundation, and employs wearables to provide 24×7 mon-
itoring of PD patients. Specifically, a Pebble watch (https://www.pebble.
com/) is provided to participants to measure wrist tremor relayed via an An-
droid app to a Cloudera-based back end for storage and analysis. The stated
goal of this study is the development of a deep longitudinal data set captur-
ing in minute detail the second-by-second variations of motor symptoms from a
population of tenths of thousands of volunteers. However, battery longevity and
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data transmission issues have set considerable challenges in attempts to capture
complete traces and the project has explored alternative strategies. Moreover,
progress towards the automatic identification of PD-related tremor episodes has
been limited by practical difficulties, such as the problem of accurately interpret-
ing raw acceleration data captured from a single body location especially when
lacking contextual information. Moreover, the ambitious target of harvesting a
complete high-resolution data stream from the wearable sets very considerable
challenges for battery longevity as devices have fewer opportunities to switch to
low-power mode.
In [27], we demonstrated the feasibility of using smartphones as a means to
assess commonly occurring motor symptoms of PD in a clinical setting. Specif-
ically, we design, develop and validate in a clinical study a prototype app on
Android implementing Part III of the mds-updrs [18]. Using the accelerometer
and touch screen sensors commonly available in modern smartphones, we are
able to carry out hand and leg tremor measurements, as well as gait and bradyki-
nesia assessments using finger tapping tasks to replicate the majority of these
tests (cf. Table 1 and Section 5.2). Other research groups have followed a similar
approach focusing on specific symptoms. Most commonly tremor measurements
are considered for example [12], [29], [34] and [35] all provide proof-of-concept
implementations of upper limb tremor estimation.
Recently, the suitability of machine learning has been investigated for the
assessment of PD. Voice samples are processed using standard machine learning
algorithms in [4] to correlate individual performance and mds-updrs score. A
deep learning approach is adopted in [20] to identify patients in ON and OFF
states using Restricted Boltzmann Machines to analyse accelerometre data; and
in [13] for the detection of bradikynesia. Both projects report encouraging
results which merit further investigation but current performance limitations
prevent these techniques from becoming an effective clinical tool.
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3. Motor Performance Assessment in PD
Currently there is no definitive test for the diagnosis of PD and only a
post-mortem examination can confirm that reported Parkinsonian symptoms
were actually caused by PD. Instead, specialists look for common signs of PD
and offer a diagnosis only after other conditions with similar presentation have
been excluded. The basis for the diagnosis is the patient’s medical history
and an examination which typically explores motor performance during various
tasks. Often, a diagnosis is not confirmed until after medication for PD is
prescribed and an improvement is recorded following a few weeks or months of
administration. Often, patients suspect of sufferring from PD will undergo MRI,
CT or SPECT brain scans, however these are used to identify and exclude other
syndromes with similar presentation rather for the diagnosis of PD as such.
During an examination the specialist would typically ask the patient to per-
form various tasks to assess the agility of arms and legs, muscle tone, gait and
balance and record the results into a table, namely the Unified Parkinsons Dis-
ease Rating Scale (UPDRS). UPDRS is a universal scale of PD symptoms and
used to comprehensively assess and document the exam. The purpose of this
record is so that clinicians be able to compare it with the patient’s future follow
up visits, or to communicate about the progression of PD symptoms in each
patient with other neurologists. UPDRS was initially introduced in 1987 and
significantly revised in 2008 as a result of extensive consultation coordinated by
the Movement Disorder Society (MDS) [18]. Although the latter is more accu-
rately referred to as the mds-updrs, the term UPDRS is often used to refer to
either. In this paper we are only considering the mds-updrs variant and for
this reason will use both terms interchangeably.
The mds-updrs is a comprehensive 50-question assessment of both motor
and non-motor symptoms associated with PD. It features four different sections,
referred to as Parts I to IV, that focus on:
I Non-motor experiences of daily living
II Motor experiences of daily living
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Figure 1: Sample questions and scoring sheet for Part III of the MDS-UPDRS.
III Motor examination
IV Motor complications
The protocol also includes the specification of a decision tree process that clini-
cians are required to follow in order to assign a particular score to each question
(each assessment must often be carried out twice, considering the left and right
side separately) after exploring each question during a brief discussion with the
patient or their carer (cf. Figure 1). The purpose of this provision is to ensure
the internal consistency of the rating scale and limit the effects of subjective
judgments by the person performing the assessment. The questions are not pre-
sented directly to the patient as they use medical terminology which may not
be clear to them. The MDS holds the copyright of the scale and its use requires
a ratings scales permissions request form to be completed and submitted to the
MDS as well as the payment of licensing fees where applicable.
Of particular significance is Part III of the mds-updrs as it is considered
the most objective and thus reliable part of the scale. Notably, the European
Medicines Agency (EMA) recognizes Part III as accepted scales to measure the
efficacy of a drug for PD. Specifically, the disease progression marker employed
in clinical trials measures an improvement of PD under a new drug as the
observed Change from Baseline of the Part III score. The score ranges between
0, corresponding to no symptoms, to 56, corresponding to maximum effects
8
typically representing full immobility. Although there is no generally accepted
score which in isolation would be adequate to lead to a PD diagnosis, different
patient groups representing different levels of symptom severity would often be
organized along the following boundaries [52]:
1. Mild PD: Part III UPDRS score 20 or below.
2. Moderate PD: Part III UPDRS score from 21 to 35.
3. Severe PD: Part III UPDRS score greater than 35.
In addition to symptoms caused by PD, chronic L-Dopa use often eventu-
ally leads to a brittle response to the medication - sometimes the medication
fails to work and the patient remains frozen and unable to move (the so-called
OFF state), sometimes the effect of the mediation is well-balanced leading to
the so-called ON state, and sometimes the medication effect is quickly overpow-
ering, causing excessive movements called L-Dopa induced dyskinesias (LID).
It is very common for a patient with mid-stage PD to fluctuate wildly between
these extremes throughout the day. Multiple treatment strategies are available
for these complications, including changes to medication, subcutaneous admin-
istration of apomorphine, intra-jejunal administration of L-Dopa or deep brain
stimulation (DBS), a continuous electrical stimulation of a surgically implanted
electrode in the brain.
While Part III of the UPDRS provides a numeric score based on the exami-
nation by a member of the clinical teeam, the 39-item Parkinson’s Disease Ques-
tionnaire (PDQ39) [25] is a self-reported measure of health status and quality
of life. The questionnaire assesses how often people affected by PD experience
difficulties across eight dimensions of daily living namely mobility, activities of
daily living, emotional well-being, stigma, social support, cognition, communi-
cations and bodily discomfort, as well as specific dimensions of functioning and
well-being. Similar to the mds-updrs the PDQ39 is under copyright and its
use requires a license from Oxford University Innovations.
Further, Hoehn & Yahr (H&Y) is a clinical rating scale introduced in 1967
that defines categories of motor function in PD, ranging from minimal or no
9
functional disability at level 0 to confinement to bed unless aided at Level 5.
However, the H&Y scale has several problems including the fact that it is not
linear so that its modern use is mainly as a means to describe patients groups
rather than quantify disease progression especially in an epidemiological setting.
For example, the severity of PD symptoms progress rapidly in diagnosed patients
with the median time taken to transit between H&Y stage 2 to 3 and 3 to 5
being 87 and 50 months respectively. Older age at diagnosis and higher mds-
updrs motor scores at baseline (both increasingly prevalent as the result of an
aging population) are associated with faster PD progression.
Finally, we note that cost of care increases manifold as PD progresses with
annual medical costs for the NHS for H&Y Stage 5 patients estimated at £30,000
per person per year at inflation adjusted prices, with average cost of £9,500
across all categories. This represents a total cost for PD of over £1.25 Billion per
annum today, projected to increase to over £1.6 Billion by 2020 (in 2014 prices).
Furthermore, these costs relate only to direct medical care which represents only
7% of the total costs of PD, with the remainder 93% split between direct non-
medical professional care (50%) and indirect informal care (43%).
4. Understanding Patients with PD
The wider adoption of cloudUPDRS by patient communities necessitates
that tests are incorporated as part of their daily routine. To understand how
to best facilitate this we carried out extensive interviews with clinicians, tech-
nologists, patients, carers and patient advocates (22 individuals in total); a web
survey with participants from the research volunteer pool of Parkinson’s UK re-
ceiving 166 unique submissions; and, three audience panels (16 participants in
total). Across all studies we recruited participants with a confirmed diagnosis of
PD and excluded individuals with generic symptoms of Parkinsonism. Patient
participants represent all H&Y levels except for the audience panels in which
participation was limited to Level 3, due to the practicalities of access to the
venue.
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The potentially transformative role of smartphone apps for PD was widely
acknowledged in interviews. The expectation of positive outcomes was closely
related to recent trends enabling the direct involvement of patients in estab-
lishing research priorities, the use of patient expertise in research, and towards
greater transparency. This perspective was often related to opportunities for
patient empowerment as expressed for example in online communities such as
PatientsLikeMe [10], suggesting that evidence-based care must cater for the
translation of evidence into practice in a manner directly accessible to and un-
derstandable by patients.
We employed the web survey to explore current phone usage patterns specif-
ically among patients and to identify potential constraints that may place barri-
ers for the adoption of the cloudUPDRS app. Responses received were primarily
from mobile phone users (96%) with 77% coming from those with a smartphone.
The majority of smartphone owners (87%) use it daily with only 14% reporting
significant difficulties. A relative small proportion of those with smartphones
(20%) use apps to track their symptoms or manage medication. The vast ma-
jority (86%) expects to make regular use of the cloudUPDRS app with 64%
expressing a preference for the test session lasting a maximum of 5 minutes,
27% accepting a test duration of 10 minutes, and 5% even longer. The major-
ity (68%) expect to make use of the app at least once per day to assess their
symptoms.
One aspect of the app design investigated in the survey is the provision of
feedback, especially considering the fact that results would inevitably indicate
a decline in performance over time. Nevertheless, over 87% of respondents
considered receiving direct feedback a key advantage of using the app despite
the expectation of a negative trend. A small number of respondents suggested
that emphasis should be on positive outcomes instead: “I don’t want my decline
to be the focus rather I’d prefer to have something that promotes my wellbeing!
I use the Speech Tool to remind me to speak louder and clearer” (Female, 45-54).
Audience panels combined elements of user experience evaluation and a wider
exploration of perceived costs and benefits of the cloudUPDRS app, which was
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Figure 2: Views of the user interface of the cloudUPDRS app showing session management,
tremor recording and finger tapping activities..
demonstrated during the sessions. Panelists identified specific problems with the
version presented, for example the potential effects of involuntary movements
common to specific patient profiles and suggested improvements. As relates to
the utility of the app and their motivation for regular use, the opportunity to
manage symptoms was an unequivocal benefit for the majority of participants
and strongly motivated their involvement.
However, access to detailed performance data was considered less important
compared against the sense of understanding offered by the experience of using
the app and the associated sense of control over the disease which this experi-
ence afforded. In particular, the set of recorded data was seen as a reminder of
the changes in the patients’ life caused by PD which they viewed as the basis
for the development of an externally validated personal narrative. An exception
to this is a small group of patients who appear committed to self-quantification
and already collected and organised self-tracking data prior to their involvement
with this study. This group valued the ability of the app to make accurate ob-
servations higher than its role as an aide-de-me´moire. All participants identified
with the strong desire to make a contribution towards defeating the disease, and
considered their contribution of personal data and their open availability for re-
search as a means to achieve this goal. As a consequence, no privacy concerns
were expressed.
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5. The cloudUPDRS System and app
The cloudUPDRS app implements a comprehensive workflow (partially de-
picted in Figure 2) that provides audio, video and textual media to guide pa-
tients and their carers to conduct the tests at home and in the community with
no requirement for supervision by a member of the clinical team. To provide
full functionality the app communicates with a data management and process-
ing back-end that enables aggregation and longitudinal analytics. Overall, the
complete cloudUPDRS system consists of:
1. A smartphone app for Android that enables patients to carry out motor
performance tests and complete a wellness self-assessment; conduct session
management; and securely submit data to the cloudUPDRS service.
2. Cloud-based scalable data collection service that ingests data from pa-
tients’ smartphones; ensures secure data management; and applies the
signal processing pipeline.
3. Data-mining toolkit for medical intelligence incorporating quantitative
and semi-structured data, and longitudinal analyses, clustering and clas-
sification; and a clinical user interface incorporating visualisation.
5.1. Presentation and Service Platfrom
The cloudUPDRS app implements a bespoke user interaction design to en-
sure that the data recorded capture the actual motor performance features as
required for the successful application of mds-updrs. Specifically, patients are
guided through a carefully orchestrated sequence of actions while the app records
sensor measurements. By requiring the execution of specific action sequences
the app restricts the degrees of freedom of individual movement and thus im-
poses structure and disambiguates user context by limiting the range of observed
behaviours.1 As a result, the recorded signal can be interpreted accurately us-
ing a small set of heuristics rather than require the use of a full context model
1The action sequences can be seen in video demonstrations available at http://www.updrs.
net/help.
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Figure 3: cloudUPDRS clinician dashboard: The specific view of the dashboard allows the
comparison of motor performance measurements computer directly by cloudUPDRS (left)
against self-reported assessments using PDQ39, which clearly show a significant divergence.
The overlaid red dots on both sides of the dashboard represent the reported times of medication
administration.
and reasoning approach [5]. Finally, the app automatically adapts to match
the specifications of its host device and incorporates a delay tolerant service to
manage data upload.
The full test administered by the cloudUPDRS app consists of 17 individual
observations, specifically kinetic, postural and resting tremor for the left and
right hand; left and right leg agility and resting tremor; single and double target
finger tapping on both sides; and, gait. During each observation period lasting
60 seconds, the patient is required to assume a specific position and perform
the prescribed movement as described in the previous paragraph. Following the
recording of these observations the patient is presented with a questionnaire
incorporating selected questions from PDQ39 and recording the time of the
most recent medication intake.
One of the key diagnostic benefits of the cloudUPDRS app is the ability
to conduct longitudinal studies. To this end, we have developed a clinician
dashboard depicted in Figure 3 which allows the investigation of aggregated
data over time for individual patients as well as over selected patient groups.
For example, a heatmap visualisation is used to show the hour-by-hour changes
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in motor performance over a period of a week with a view to provide an overall
assesement of disease progression.
The cloudUPDRS service is engineered to facilitate scalable performance
by adopting the microservices architecture [44]. This approach is set in con-
trast to traditional monolithic web applications and aims to maximise oppor-
tunities for vertical decomposition and scaling-out, which are critical for high
performance and service resilience in data intensive situations. cloudUPDRS
microservices are implemented as composite Docker containers, are loosely cou-
pled and employ lightweight communication and coordination mechanisms such
as the Consumer-Driven Contract pattern. System componentization is en-
forced via versioning of published RESTful interfaces and sandboxed instances
of the service can be deployed automatically to cater for data isolation between
distinct regulatory domains. cloudUPDRS microservices are deployed as docker
containers (cf. https://www.docker.com/) although internal implementation
details vary to match the specific preferences and expertise of project partners
responsible for their implementation and their suitability for the task in hand.
For example, while the data collection and signal processing APIs are imple-
mented using python and django REST within an nginx/gunicorn container,
semi-structured longitudinal analytics are implemented as Ruby bundles. The
overall service architecture has been designed for scalability so that real-time
streams captured for example during concurrent patient consultations can be
integrated on the fly with archival information from the longitudinal datastore
service. To facilitate this modus operandi, we provide structured workflows im-
plemented through microservices following the lambda architecture [39], which
facilitates the efficient fusion of real-time and archival data on the fly.
5.2. Bio-signal Processing
Precise assessment of tremor, bradykinesia and gait is typically carried out
using laboratory equipment for example tailor-made biomedical data acquisition
systems incorporating transducers such as high-frequency/high-accuracy ac-
celerometers and gyroscopes, signal amplifiers and filters and high-performance
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Table 1: Analytics toolbox signal processing functions and correspondence to the sections of
the mds-updrs.
Analytic Function mds-updrs Section
Rest Tremor 3.17 (rest tremor amplitude)
Postural Tremor 3.15 (postural tremor of the hands)
Action Tremor 3.16 (kinetic tremor of the hands)
Pronation—supination
Movements
3.6 (pronation—supination
movements of the hands)
Leg agility 3.8 (leg agility)
Finger tapping 3.3 (rigidity) & 3.4 (finger tapping)
Gait 3.10 (gait) & 3.11 (freezing of gait)
analog-to-digital converters. The captured signal is analysed subsequently by
specialist commercial software such as Spike 2 by Cambridge Electronic Design
Ltd with the total cost of a complete system rising to tenths of thousands.
Laboratory based clinical rating however is constrained by the requirement
that the patient is present in the clinic, and in practice can only be carried
out as a “snap-shot” assessment. In [27] we show that the sensor, clock and
data acquisition hardware of a low-end smartphone capture data with sufficient
accuracy to precisely quantify the magnitude of PD motor symptoms across the
majority of the tests included in Part III of the mds-updrs by comparing its
performance against results obtained using a biomedical analytics system by
CED. In cloudUPDRS we automate the methodology presented in [27] as a be-
spoke cloud-based data analytics service [15]. For completeness of presentation,
we briefly summarise the main features of this system here.
5.2.1. Tremor
Tremor measurements are recorded for both hands at rest, at posture and in
action as listed in Table 1. For rest tremor measurements, users are asked to re-
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lax their hands on their lap in a supine position while the phone is lying in their
palm. For the postural tremor measurements patients are guided to keep their
arm outstretched directly on their front while holding the smartphone. Finally,
for action tremor measurements they are required to hold the phone and move
it between the chest and the fully outstretched position on their front. In all
cases, acceleration is recorded along three axes in m/s2 at the maximum sup-
ported sampling rate (at least 50 Hz) and timestamped at maximum resolution
(typically microseconds). Tremor is calculated as the cumulative magnitude of
the scalar sum acceleration across three axes for all frequencies between 2 Hz
and 10 Hz. To obtain this power spectrum the signal is first filtered with a But-
terworth high-pass second order filter at 2 Hz and the Fast Fourier Transform
(FFT) is subsequently applied to the filtered waveform data.
5.2.2. Bradykinesia
Mds-updrs assess bradykinesia, or else the slowness of movement, through
three different factors: (i) pronation-supination movements, (ii) leg agility, and
(iii) finger tapping. In the first test patients are asked to hold the phone and
perform alternating pronation-supination movements, that is rotating the palm
of the hand toward the inside so that it is facing downward and then toward the
outside so that the palm is facing upward, as fast and as fully as possible. Leg
agility measurements require the phone to be placed on the thigh of the patient
while seated, holding the phone lightly with the ipsilateral hand, while raising
and stomping the foot on the ground as high and as fast as possible. During
both tests the phone is recording acceleration data in a manner similar to the
tremor tests. The assessment of the pronation-supination movements and leg
agility tests requires the estimation of the frequency and power of movement.
To obtain these, the toolkit first removes DC offset and applies a Butterworth
low-pass second order filter at 4 Hz in order to exclude most of the tremor.
Subsequently, the power of the movement is calculated as the total amplitude
between 0 Hz and 4 Hz and the frequency derived from the power spectrum.
Finger tapping performance is assessed in two tests using single and dual
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targets presented on the screen of the phone at set locations with patients at-
tempting to tap them as fast and as accurately as possible (alternating between
targets in the dual-target case). When tapping accidentally occurs outside the
screen area the test is repeated. The touch-sensitive screen of the smartphone
is used to collect the information used for performance calculations, specifically
the timing of each touch event, its duration, the direction of movement (upwards
or downwards), the coordinates on the phone screen, and the amount of pressure
applied are recorded. For the two-target variant it is necessary that the distance
between targets be at a specific distance irrespective of the size of the screen or
of the device. To estimate finger tapping performance the analytical functions
first identify all touch events and employ the associated timestamps to estimate
tap frequency (taps per second), the mean hand movement time between taps
(in milliseconds), and the actual movement distance between alternative tapings
in the dual-target case (in centimetres).
5.2.3. Gait
Mds-updrs assesses gait by considering multiple behaviours including stride
amplitude and speed, height of foot lift and heel strike, and turning and arm
swing [63]. The cloudUPDRS variant of this test requires the patient to walk
along a straight line for five meters, turn around and return to the point of
departure, while the smartphone is positioned either in their belt or trousers
pocket. Since it is only possible to measure acceleration data from a single
point at the waistline we employ the techniques in [36, 37] to estimate stride
frequency and length, velocity and turning time.
However, in comparisons against assessment by an experience clinician pre-
sented in [27] individual metrics were only weakly correlated to the correspond-
ing Section 3.10 mds-updrs score. Since it is not possible to capture detailed
information about the movement of the leg relative to the foot and the arms,
the metrics calculated simply identify characterises of body types. Although
perhaps not as useful in the context of calculating the mds-updrs score this
data is still of interest for the exploration of new digital biomarkers related for
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example to freezing that can be useful for the development of disease progression
indicators and thus we consider this feature to merit further investigation.
6. Certification
As noted in Section 2, there are several research, wellness and self-tracking
apps for PD available on both major smartphone platforms and many more
released selectively for research. The vast majority of these apps do not conform
to the safety, quality, performance and regulatory requirements set for medical
devices and as such can only be employed either to encourage a healthy lifestyle
or for research purposes correspondingly — but are not tools that can be used to
support medical diagnosis. This fact is often explicitly reflected in their terms
and conditions of use for example, quoting from a popular PD app “we cannot,
and thus we do not, guarantee or promise that you will personally receive any
direct benefits.”
Medical devices are regulated and must conform to rules enforced by re-
gional legislation. Within the European Union, harmonisation of regulations
across member countries is facilitated by the Medical Devices Directive (MDD),
which provide the blueprint for country–specific legislation. Although the MDD
considers situations when software would be treated as a medical device it does
not explicitly examine smartphone apps and so its provisions are open to inter-
pretation, an issue that we address in this section. Further, the MDD requires
that each member state establishes a Competent Authority to provide guidance
and enforce regulation of medical devices and in the UK this responsibility lies
with the Medicines and Healthcare products Regulatory Agency (MHRA).
Under Article 1 Clause 2(a) of the MDD a medical device is defined as “any
instrument, apparatus, appliance, software, material or other article, whether
used alone or in combination, including the software intended by its manufac-
turer to be used specifically for diagnostic and/or therapeutic purposes.” The
current interpretation of this definition by the MHRA as relating to apps implies
that “if the [mobile] application is intended to carry out further calculations,
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enhancements or interpretations of entered/captured patient data, [· · · ] it will
be a Medical Device. If it carries out complex calculations, which replaces the
clinician’s own calculation and which will therefore be relied upon, then it will
certainly be considered a Medical Device.” Hence, the features of the cloud-
UPDRS app clearly place it within the provisions of the MDD. For certification
purposes, the named publisher of the app on the selected platform store is con-
sidered its manufacturer as defined by the MDD, and thus the party obliged to
ensure conformity with the provisions of the directive.
Hence, according to the MDD the cloudUPDRS app is a Class 1 medical
device that is, an active transient non-invasive instrument. Class 1 devices
are considered lower risk and as such as less closely regulated. In this case,
certification requires that the app meets the Essential Requirements outlined in
Annex I of the MDD including:
i evidence of software development in compliance with ISO/IEC 62304,
ii comprehensive documentation ensuring that it can be used safely and ap-
propriately by patients, and
iii implementation of quality management processes which ensure that the de-
vice can be safely marketed as a consumer product.
Moreover, any software developed under the provisions of the MDD should also
comply with European privacy regulations, which in this case in particular ne-
cessitates the conduct of a Privacy Impact Assessment (PIA) according to the
provisions of the code of practice detailed in the PIA Handbook published by
the Information Commissioner’s Office (ICO). Clearly, these requirements add
considerable complexity, cost and overhead to the development process and in
particular require that when a new version of the app is published a full set
of conformity checks and software tests must be carried out, and updated doc-
umentation produced however small the changes. Certainly, they specifically
exclude testing with users outside a strictly controlled setting for example, as
common with lean development approaches. As a consequence, successful certi-
fication requires the investment of considerable additional effort and resources
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and although we have not precisely audited these effects, in the case of cloud-
UPDRS has clearly resulted in a longer software development period by several
months.
It is interesting to consider each of these requirements in more detail. ISO/IEC
62304 is an international standard which specifies the life-cycle requirements for
the development of medical software in general and software incorporated in
medical devices in particular. The standard describes provisions according to
the potential of the software to create a hazard that can potentially result in in-
jury. cloudUPDRS is classified as Safety Class A, which represents a lower level
of risk to health. Nevertheless, despite the relatively less stringent provisions for
this class, the standard still requires a structured software development process
with distinct phases prescribed for planning, requirements analysis, design and
unit testing, which is often at odds with modern agile software development
processes commonly employed for mobile apps.
The key enabler for cloudUPDRS to satisfy the ISO requirements while not
sacrificing the considerable advantages of agile methods for mobile, is to employ
software development tools that enforce structured workflows. For example, the
permissions and change control elements of our development process enforced
a specific sequence of steps to be taken so that patches are only applied after
they have passed checks successfully. Further, we employed popular software
development tools in such a way so as to automatically generate the required
documentation at every iteration. The overall goal of this practice is to ensure
traceability and transparency throughout the life-cycle of the software especially
in dealing with software faults and before the incorporation of new features.
Although this leads to a more cumbersome process from the developer point of
view, this objective can be achieved through the use of collaborative design tools,
issue trackers, reports, change control and testing workflows enforced through
software automation. In cloudUPDRS we implemented such control, review,
approval and documentation mechanisms using a variety of common industry-
standard tools including Atlassian Jira, Pivotal Tracker, github and Circle CI
which together can provide the required level of auditing and automation.
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The second requirement for certification however cannot be automated as
it relates to the implementation of a risk management process to determine
the safety of the medical device and must be carried out by the manufacturer
throughout the product life-cycle. In the context of the MDD, risk management
would commonly be carried out according to the provisions of ISO 14971. From
the software development perspective, compliance requires regular, typically
weekly, meetings of a risk assessment panel incorporating technical, medical
and administrative representatives. The role of this panel is to consider the
implications of current and planned developments, develop a mitigation strat-
egy and monitor acceptable hazards that cannot be completely eradicated. The
documentation produced automatically from the software development process
described above provides significant input to the discussions among panel mem-
bers but additional issues raised by individual members with responsibility for
specific risk areas are also considered. The work of the panel results into a risk
assessment document that identifies individual risks, the likelihood that they
might occur and an assessment of their potential impact. Measures to alleviate
these risks must also be considered and implemented as appropriate. The final
output of this process is the maintenance of the so-called risk management file
for cloudUPDRS.
Finally, the third requirement for certification is typically interpreted as
meeting the provisions of ISO 13485 which specifies the quality management
system that a manufacturer should meet. Although in the case of cloudUPDRS
this added significantly to the overhead of certification due to the fact that for
the manufacturer this was the first medical device registered, this requirements
does not refer directly to the individual device but rather sets requirements at
the organizational level, specifying specific processes to be in place, identifying
quality assurance roles and commitments.
Last but not least, conducting the PIA has several technical implications
relating to architecture design decisions. In particular, the PIA must clearly
detail the information flows within the system and consider each step from the
point of view of privacy and design mechanisms that address these risks. This
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requires the careful design of security provisions for example from the begin-
ning of the project and their frequent review to follow changing project needs.
In fact, this requirement represents best practice in software development and
the PIA should simply provide an explicit reminder and record of the decisions
made. Where design decisions do not fully address patient needs a mitigation
plan should be developed. In the case of cloudUPDRS, conducting the PIA
upfront paid dividends later in the project as it represents a key document re-
quired to obtain approval for clinical studies. Having said that, in May 2018 the
new General Data Protection Regulation (GDPR) will come into force in the
EU, which has considerable long-term implications for cloudUPDRS. While a
full discussion of the architectural, operational and organizational modifications
required to become GDPR-compliant is beyond the score of this paper, it is nev-
ertheless appropriate to point out that it has far reaching technical implications
for example to support the right to be forgotten and especially data portability.
cloudUPDRS received medical device status in the UK, and thus in the EU,
in May 2016.
7. Learning Test Movements
As noted in Section 3, disease progression assessments in PD are typically
carried out bi-annually under the supervision of a qualified member of clinical
staff who ensures that patients follow closely the actions dictated by Part III
of the mds-updrs protocol. This is also the case in clinical studies where in
addition to providing supervision, clinical and research staff would also operate
the equipment used to carry out performance measurements and subsequently
process the data using specialist software. In Section 5, we discussed how the
cloudUPDRS app extends this practice enabling a patient to carry out precise
measurements of motor performance unsupervised using a smartphone. Indeed,
when conducting self-assessments at home using cloudUPDRS supervision by
an expert is neither readily available nor desirable as it would nullify the cost
benefits of this approach. Nevertheless, in order to ensure accurate symptom
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Figure 4: Typical tremor measurement trace representing a high quality observation.
assessment with cloudUPDRS it is necessary to establish whether the prescribed
movements have been followed closely during data recording.
To address this lack of expert supervision and ascertain the fact that data
has been captured under the appropriate circumstances, cloudUPDRS combines
two methods that operate in tandem. Initially, the patient is guided by the user
experience design presented in Section 5, which provides support in performing
the actions accurately and steers the user through the process. While this ap-
proach has produced positive results, full compliance with the prescribed actions
still cannot be guaranteed or confirmed. Hence, cloudUPDRS supplements this
user interaction design with the development of a mechanism used to verify the
quality of the data collected. Specifically, we introduce a deep learning method-
ology which aims to replace human supervision by providing a means to confirm
that the recordings submitted have been captured while the patient performs
the required actions correctly2. Failure to do so would produce bio-signal mea-
surements that are not representative of the intended tremor type and are likely
to result in erroneous scoring.
To achieve this, we adopt a deep learning methodology [19], in this case Re-
2In the case of the one- and two-finger tapping tests it is relatively straightforward to
identify when the process has been followed accurately directly from the output of the bio-
signal processing of Section 5.2.
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current Convolutional Neural Networks [1], to enable the cloudUPDRS system
to learn movement features associated with a high quality signal (cf. Figure 4 for
a visual representation of the patterns of acceleration typically observed), and
alert the user when an observation has not been captured under satisfactory con-
ditions. Enabled by recent advances in general-purpose computing using graph-
ics processing units and related algorithmic developments, this methodological
approach employs multiple hidden layers to obtain notable results permitting
neural networks to identify preferred features directly from the raw signals. This
aspect of the selected methodology appears especially well-suited to the data
quality issue under consideration.
The data set used to investigate the performance of this approach is taken
from the first cohort of patients enrolled in the cloudUPDRS trials (8 male and
4 female). Specifically, we consider 227 distinct test sessions conducted over a
period of three months (June to August 2016). Signals were collected from 9
different phone models providing acceleration measurements with a minimum
sampling rate of 50 Hz, implemented using the data collection code base of the
cloudUPDRS app (other source code elements not affecting data collection were
modified during this period). Results are reported specifically for pronation-
supination observations of the right hand, without loss of generality for the
purposes of this paper. Data captured by the app are normalised but no other
pre-processing is performed at this stage.
7.1. Rationale and Overview
To formulate an algorithmic solution, we re-frame the problem of captured
data verification as one of binary classification. Specifically, the goal of the ver-
ification task is to discriminate between high-quality observations/signals and
lower-quality sensor recordings captured during movements that do not closely
adhere to the guidance of the mds-updrs protocol. To this end, we employ
a training data set of observations representing both acceptable and unsuit-
able cases with known data quality characteristics, guaranteed by the fact that
they are collected by the app under controlled conditions or inspected manually.
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Figure 5: DMLP neural network architecture employed by [57].
From this data set, features that are distinct within each class are identified al-
gorithmically. Subsequently, the obtained representations are employed to test
new observation data submitted by patients via the app: submissions classified
as offering adequate quality are accepted and forwarded to the appropriate mi-
croservices for data ingestion and signal processing; otherwise they are rejected
and excluded from further consideration.
Our initial experiments with this methodology were presented in [57] where
we employed Deep Multilayer Perceptrons (DMLP), as the one shown in Fig-
ure 5, using the middle segment of the signal (Figure 6) to solve the classification
problem. The work presented in this paper, extends [57] in two significant ways.
First, the software has been re-implemented from first principles using Tensor-
Flow [2] so that it can be fully incorporated into the app running on the mobile
device rather than be applied at the service back-end. This is possible due to
the fact that TesorFlow provides strong support for mobile platforms and be-
cause the classification process has two distinct stages: an initial model training
phase representing the most computationally intensive task followed by a sample
assessment phase which is relatively lightweight for modern smartphone hard-
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Original x, y, z features
512 dataset with the 
artificial feature m
256 dataset with the 
artificial feature m
Figure 6: Inputs to the DMLP neural network architectures employed by [57] consist of signal
segments along the x, y, z acceleration axes together with the acceleration magnitude m.
ware. As such, using TensorFlow the model can be constructed off-line using
archival observation data for training and later incorporated in the app, which
can conduct real-time quality assessments at the time of data recording and in-
teractively request the repeat of specific individual observations as appropriate
to ensure that all submitted tests are usable.
Second, although we obtained good performance using the approach pre-
sented in [57], the specific neural network architecture employed examines only
a segment around the mid-section of the recorded signal (cf. Figure 6). Con-
sidering the significant changes observed in time during a complete observation
trace as detailed in Section 8, notably the considerable drop in the power of the
dominant tremor frequency for example, as depicted in Figure 11, it is clearly
preferable to process the full trace for the duration of the test. To this end
and to take into account the temporal aspect of the input signal, we introduce
in this paper a novel deep learning architecture using Recurrent Convolutional
Neural Networks (RCNN) [41].
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Figure 7: Sliding window of length 256 with 128-overlap applied on the recorded signals along
the three acceleration axes to create the dataset used in this paper. Left side shows the dataset
in a 256 × 3 matrix form to feed the RCNN. Right side shows the same data in a 768 × 1
vector form as required to feed the rest of the architectures.
7.2. Deep Learning Architecture
There are two main observations that guided the development of a new
architecture to replace the work presented in [57]. First, in [57] each individual
axis of acceleration is considered separately; that is four separate DMLPs are
generated and trained for each of the x, y and z coordinates as well as the
derived feature m representing the magnitude of acceleration (cf. Figure 6).
Second, the input vector for each of the four neural networks constructed is a
256 or 512 long segment taken from the middle section of each signal trace rather
than sampling the full signal (cf. Figure 6). As a consequence, the temporal
features of the captured signal are not taken into consideration. At the time,
both were reasonable options and in practice able to provide good performance.
In this paper we adopt an alternative approach, whereby we examine all
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three signal elements at the same time so as to unlock the full spatiotemporal
characteristics of the complete signal. The practical implication of this is that
the generated data takes the form of a matrix rather than vector, which is
the typical formulation to feed a classifier. To reflect this change, we opt to
replace the four DMLP architectures employed previously with one based on
Convolutional Neural Networks (CNN) [68, 19], because they provide better
performance with multidimensional (grid like) inputs. Moreover, to account for
the temporal properties of the signal we employ Recurrent Neural Networks
(RNN) [1], which are eminently suitable for processing temporal sequences. By
using both convolution operations and recurrence relations we aim to exploit
the whole range of information that the data has to offer, including local and
temporal characteristics.
The synergy of CNN and RNN also provides another advantage over Mul-
tilayer Perceptrons (MLP), such as the DMLP used in [57]. It relates to the
capability of MLP related architectures to deal with variations in the input
space. For example, translation invariance relates to small changes in the input
space which, however, require a lot of computation from MLPs to learn. This
is because networks, like MLP and DMLP, have no shared weights or shared
parameters, so small variations in a multidimensional input imply that a DMLP
would have to learn all local features from scratch. In contrast, architectures
that share weights and parameters, such as CNNs, are more robust to such
variations in the input space.
7.2.1. Convolutional Neural Networks (CNN)
CNNs can detect and extract local informative patterns with fewer parame-
ters than MLPs by iteratively traversing a smaller set of weights, called kernels,
on n-dimensional input grids. This means that CNNs really shine when we
have a grid or volume like input, and the features in this input space are locally
correlated. CNNs are a good fit for the binary classification problem we are con-
sidering in this paper due to the fact that they exploit three distinct concepts,
namely sparse interactions, parameter sharing and equivariant representations.
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Sparse connectivity, or sparse weights, refers to the fact that the kernel
used in convolution operations is much smaller than the input, thus making the
weights w.r.t. the input quite sparse. For example, using a 3 × 3 kernel on a
grid of inputs with size 256× 3 requires only 9 connections for the detection of
patterns and other meaningful features, as opposed to an order of magnitudes
more connections for fully connected layers. By storing less parameters (weights)
for our feature representation not only we optimize storage but we also improve
the efficiency of the representation [19].
Parameter sharing, or tied weights, refers to the fact that CNNs are learning
only one set of parameters for every location in the input, as opposed to MLPs
where one parameter is required for each input part. Parameter sharing brings
considerable improvements in storage as it is only necessary to store a few pa-
rameters corresponding to the weights, instead of a full matrix of parameters for
a fully connected layer. As a consequence of parameter sharing, CNNs achieve
equivariance to translation, essentially a time-line that highlights when specific
features are present in the input. For example, when the same feature appears
at different times in the input, the kernel produces the same representation in
the output at the corresponding times.
7.2.2. Recurrent Neural Networks (RNNs)
RNNs are generally considered the best choice when dealing with sequences
of symbolic, non-symbolic or mixed data, as happens for example in natural
language processing, handwriting recognition and speech processing [1]. RNNs
are more successful than fully connected or convolutional alternatives, because
they operate efficiently over sequences and thus are not constrained by input
size or fixed number of computational steps. Similar to CNNs that scan the
multidimensional grid input and share weights locally, RNNs scan the input
sequences and share the weights in time. Sharing weights across time makes
RNNs sensitive not only to specific input patterns but also specific input se-
quences. Although many RNN variants have been explored in the literature [1],
in this paper we draw inspiration from Recurrent Convolutional Neural Net-
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works (RCNN) [41] to develop our particular architecture.
We follow [41] in our implementation, however our architecture has some
distinct features. First, there is the extra addition of a fully connected layer
before the network output, as depicted in Figure 8. Second, in contrast to [41]
we do not use pooling layers or dropout as our investigation suggests that tremor
appears to be sensitive to this type of stochastic noise injection. Furthermore,
we opt for a modular topological approach, as suggested in [59, 21], which
groups layers into modules so that they can be easily replicated across the whole
network. We have used batch normalization after every convolutional layer, as
seen in Figures 9 and 10, because it has the property to stabilize the gradients;
thus, alleviating both the exploding and the vanishing gradients problems [1].
Lastly, recurrence happens in the convolutional layers according to Figure 10,
where state is shared across convolutional steps and also the original input of
the shared states is added to each of the steps. We have named this recurrence
module Recurrent Convolutional Layer (RCL) and can be identified in Figure 10.
Convolution BatchNorm ReLU (CBR) is also a key ingredient of the RCNN and
can be seen in Figure 9.
To take advantage of the synergy between convolutional and recurrent net-
works we section the input space into equally sized chunks so that the CNN
can fully exploit the local features. Time–order of these chunks is maintained
so that the RNN can exploit the temporal aspect of the slices.
To get our data into the required form, a sliding window of length 256 with
128-overlap is employed on each individual session of observations out of 227.
For the benchmark algorithms we have used a flattened version of the 256 × 3
input, as can be seen in Figure 7, in order to form an input vector. Previous
experimentation on cloudUPDRS suggested that this choice outperforms other
options, such as a length of 512 as reported in [57].
Moreover, our experiments suggest that the RCNN architecture that per-
forms the best has the following structure:
• One input layer of size 256× 3, followed by
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• One CBR layer, followed by
• Two recurrent convolutional layers (RCLs) with a kernel size of 9× 3 and
32 and 64 filters respectively, followed by
• One flattening layer where the layer is vectorized, followed by
• One fully connected layer of size 512 with Batch Normalisation and ReLU,
followed by
• One softmax layer of size 2
Each RCL has 3 time steps with kernels of the same size as their input, as
can be seen in Figure 10. All layers use the same activation function namely
the Rectified Linear Unit (ReLU), which takes any input and produces the
maximum value between the input itself and zero. This form of activation
function is very popular because it helps alleviating the well known vanishing
gradients problem and also creates sparse connections in the hidden layers of
the network, limiting values to zero.
Figure 8: RCNN architecture with the size of each layer at the bottom in square brackets,
where the notation [n×m] denotes the size of the matrix. The internal structure of the CBR
and RCL modules is presented in Figures 9 and 10.
7.3. Classifier Training and Validation
Training the above architecture requires comparing the output yˆ of the con-
structed deep network against the desired output y, which in the cloudUPDRS
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Figure 9: Convolution BatchNormalize and ReLU (CBR)
case represents the appropriate quality class label that the network should pro-
duce, i.e. accept or reject the signal window presented at the input. This
information is used in the so-called cost, or objective, function that the RCNN
aims to minimise. Here we adopt the categorical cross-entropy L as the objective
function, defined as L(y, yˆ) = −y log yˆ − (1− y) log(1− yˆ).
The final step in the process is the application of the backpropagation algo-
rithm [62] which enables the network to learn the distribution that generated
the training data. Backpropagation (BP) employs the chain rule to calculate
the derivatives of the objective function with respect to each connection weight
between neurons, and uses this information to update the weights. In this work
we have used a variant of the standard BP: the Stochastic Gradient Descent
(SGD) with momentum [58], as it has been shown by [65] that deep networks
trained with this method are able to provide better generalization than other
methods tested.
Training is carried out on the full signal across the three acceleration axes
at the same time. As the three signal components may be of different lengths,
as mentioned above, we have employed a sliding window of size 256 with 128
overlap ensuring that we have segments of the same length and also preserving
the temporal aspect of the signal; thus making each the input a grid like struc-
ture (cf. Figure 7). As overlapping sliding windows are used, the order of the
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Figure 10: Recurrent Convolutional Layer (RCL)
windows is preserved when training so as to exploit the temporal features of the
signal. Further, the so-called leave-one-out method [3] is combined with early
stopping to asses the true predictive power each learning algorithm has on all
of the data and to reduce the risk of overfitting. The choice of this approach
reflects the fact that the data set under investigation was based on observations
from 227 patient sessions, which is relatively low in this context.
Each iteration of leave-one-(session)-out process involves the exclusion of a
single session from the data set, training the classifier on the remaining ses-
34
sions and testing on performance on the omitted. Consequently, the RCNN of
Section 7.2 is trained as many times as the sessions available in the data set,
in this case 227 times. One limitation of this technique is that it can become
biased on the weight initialization. To address this issue the process is repeated
ten times using different initial random weights and the mean is used as the
overall performance metric. Thus, the experiments summarized below are con-
ducted using ten cycles of leave-one-(session)-out cross-validation, so that 2, 270
classifiers have been trained and averaged.
The early stopping heuristic applied ensures that the learning process is ter-
minated when it reaches a certain predefined threshold. Specifically, we employ
three criteria: (i) the categorical cross-entropy falls below 0.001; (ii) training
classification success reaches 100%; or, (iii) the learning process has reached
200 iterations. The benefit of using early stopping is that it prevents the RCNN
classifier from memorizing counter-productive characteristics discovered in cer-
tain samples, especially when these are spurious or irrelevant for the accurate
determination of high versus low quality observations. This technique works
well when used in conjunction to leave-one-out as it ensures that the RCNN is
not over trained [42] on any part of the data set.
To validate the effectiveness of the cloudUPDRS approach we compare its
performance against several well-established alternatives selected for their recent
success in industrial systems or in highly-regarded competitions such as Kaggle.
Full details are provided in Section 7.4 below.
7.4. Experiments and Results
The deep learning approach described in Sections 7.2 and 7.3 is implemented
using the computational graph engine Tensorflow [2]. Training was carried out
on an array of nvidia K40 GPUs achieving a 20-fold speedup against a standard
multi-core CPU. To provide a baseline against which to evaluate our approach
we compare its performance with the following classifiers implemented using
the scikit-learn [49] machine learning library: (i) Gaussian Naive Bayes [46];
(ii) Bernoulli Naive Bayes [46]; (iii) Random Forest Classifier [9] which employs
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Table 2: Classification reports with F1 score and Area Under the Precision-Recall curve
(AUC).
Classifiers Accuracy F1-score AUC
ExtraTrees 0.73 0.79 0.83
BernoulliNB 0.73 0.79 0.83
RandomForest 0.73 0.79 0.83
GradientBoosting 0.72 0.80 0.83
Bagging 0.72 0.78 0.83
AdaBoost 0.66 0.75 0.81
GaussianNB 0.69 0.75 0.83
DMLP 0.75 0.81 0.85
RCNN 0.78 0.82 0.87
an ensemble of random decision trees each selected from a sample drawn with
replacement; (iv) Extra Trees Classifier [17] is a variation of random forest with
thresholds randomly drawn for each candidate feature; (v) AdaBoost Classifier
[70] is a meta-estimator which adjusts classifier weights so as to improve learning
from difficult classes; (vi) Bagging Classifier [8] is also a meta-estimator which
operates on random subsets of the training data to reach a final prediction
by aggregating their results; and (vii) Gradient Boosting Classifier [16] which
performs optimization of arbitrary differentiable loss functions. Furthermore we
are benchmarking against the main algorithm from our previous work [57], the
DMLP, which has been reproduced with the exact same settings as before, the
only difference being the input layer, which is now 786 instead of 256 or 512.
As you can see from Table 2, the proposed RCNN–based approach outper-
forms all other methods on all the metrics used to assess overall classification
success. The F1 score represents the harmonic mean between the precision and
recall and AUC is the area under the precision-recall curve.
Further, the confusion scores from Table 3 shows that the proposed RCNN
outperforms all the rest mostly because it is the only method that can actually
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Table 3: Confusion matrix for the classifiers compared (averaged performance). Labels: T/F
True/False and P/N Positive/Negative.
TP (%) FN (%) TN (%) FP (%)
ExtraTrees 141.52 93 8.98 6 13.36 17 63.14 82
BernoulliNB 146.23 96 4.27 3 6.92 8 69.58 91
RandomForest 138.39 91 12.11 8 16.19 20 60.31 79
GradientBoosting 146.02 96 4.48 3 8.12 10 68.38 89
Bagging 135.58 89 14.92 10 18.03 23 58.47 76
AdaBoost 128.0 84 22.5 15 17.34 22 59.16 77
GaussianNB 116.01 76 34.49 23 35.41 45 41.09 54
DMLP 135.73 89 15.77 10 28.19 37 49.31 63
RCNN 133.22 87 18.28 12 38.38 50 39.12 50
differentiate between positive and negative observations. We have to take into
account that this is quite an unbalanced dataset, we have in total 5691 signal
windows, out of which 3765 are positive and 1926 negative. If you look closely
at the BernoulliNR and GradientBoosting, they have very good True Positive
scores but at the cost of True Negatives. This means that they are very biased
towards predicting positives, classifying low quality recordings as high quality
useful signals.
In contrast, the RCNN produces more balanced performance, recognizing
larger number of low quality recordings than other methods, and producing a
lower value for the false positives compared to other classifiers. This is reflected
in the overall RCNN performance, as shown in Table 2, in terms of its Accuracy,
F1-score and AUC value.
8. The cloudUPDRS Quick Test
In this section, we turn our attention onto the development of methods that
achieve significant reductions in test duration so as to enable patients to use
cloudUPDRS on a daily basis. As suggested by the user studies summarised in
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Section 4, the majority of patients identified a maximum of 5 minutes as the
desirable duration for the test. However, even after the initial familiarisation
period the full implementation of the procedure typically requires 25 minutes, an
estimate that has been confirmed from system logs and independently through
user feedback. The critical influence of test duration on user adoption rates
was further confirmed during the initial three months of field testing. While
the majority of participants carried out tests regularly during the first week
following the commission of the app, compliance rates dropped sharply by the
end of the third week, and only one out of the 12 participants continued to carry
out tests at the end of the three-month testing period.
8.1. Test Duration and Characteristics
Recall from Section 5 that according to the mds-updrs protocol each in-
dividual observation requires 60 seconds of recording and the full test consists
of 17 observations, in addition to the medication and well-being questionnaire.
Clearly, to reduce the overall duration of the test there are two main options
namely to shorten the recording time for individual observations or to reduce the
number of observations carried out by selecting a subgroup of the full 17-item
set. The final questionnaire requires approximately 30 seconds and is always
required because it is used to track medication.
First, consider the option to reduce the length of individual observations
without loss of precision in the estimation of motor performance. Specifically,
we investigate whether the 60 second observation period set by the mds-updrs
protocol is necessary or instead consistent scoring can be still maintained after
significantly reducing its duration. To this end, we conduct observations of
motor performance for alternative recording periods of 20 and 40 seconds and
compare these against measurements carried out for the the full 60 seconds.
Tremor and bradykinesia performance metrics were calculated for all observation
types in our test data set consisting of 133 full tests carried out by 35 different
individuals. In the remainder of this section we report scores calculated for
tremor power at rest for the right hand, without loss of generality and so as to
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Figure 11: Change in recorded tremor power between tests of 60 and 20 seconds.
specifically quantify our findings.
Figure 11 summarises the results of this analysis and demonstrates that for
the majority of patients a shorter observation period results in a significant
change of their reported motor performance. Specifically, Figure 11 shows that
when the recording period is reduced from 60 to 20 seconds the power of the
tremor for 60% of the patients is reduced by more than 10%. Similar results
are obtained when the observation length is reduced to 40 seconds with the
same magnitude of change observed for 35% of the participants in this case.
These changes in motor performance for shorter recording periods correspond
to significant changes in the estimated mds-updrs score for a single observation
ranging between 1 and 2.5 points on the mds-updrs scale. This difference in
the actual clinical score corresponds to an average expected disease progression
over a six- and twelve-month period respectively, thus representing a significant
error in precisely assessing motor performance.
These results clearly imply that that it is necessary to maintain the full
60 second recording period for each individual observation. Relevant clinical
literature considering the mds-updrs does not appear to offer explicit justifica-
tion for this performance. However, it seems that this is an observation readily
confirmed by experienced clinicians such as those participating in focus groups
conducted by cloudUPDRS (cf. Section 4). In particular, it was suggested that
the longer duration is required in most cases to cause mild fatigue that reveals
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the true characteristics of motor performance. In any case, the option to de-
velop the quick test by reducing the duration of individual observations does
not appear viable and alternatives must be considered.
8.2. Identifying Clinically Distinct Factors
Clinical investigations of the mds-updrs scale reported in the medical lit-
erature have identified a smaller group of clinically distinct factors, typically
five to six, that provide high correlation to the overall score of the motor ex-
amination of Part III of the mds-updrs [60, 61]. This observation corroborates
the possibility to develop the quick test by reducing the number of individual
observations to a much restricted group, which correlates well with the overall
patient score. Furthermore, note that the mds-updrs protocol was designed
to explore exhaustively the full range of possible motor symptoms caused by
PD, but a specific individual would typically present a smaller number of symp-
toms (especially in earlier stages of PD) that dominate their mds-updrs score
and that remain relatively stable over a time frame of a few months. Indeed,
a common observation is that PD motor symptoms are asymmetric [7, 51] for
example, for a particular patient one side can be significantly affected by tremor
while the opposite side may not be affected at all thus contributing zero units
towards their mds-updrs score.
Motivated by this observation, we develop a methodology using standard
machine learning methods that successfully identify the appropriate subgroup
of observations for a specific patient which offer the highest predictive power
of their overall motor performance. Upon enrolment in cloudUPDRS, patients
are required to carry out the full test at least five times during the first week of
monitoring. At the end of this calibration period we use the data of the full test
to conduct a feature importance analysis. Specifically, following [17] we apply an
ensemble of randomized decision trees on multiple sub-samples of the test data
improving its predictive accuracy through averaging and over-fitting control. We
then rank individual observations according to the relative importance of their
corresponding features (two and three features per tremor and bradykinesia test
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respectively). Finally, we select the subgroup of top performing observations
which account for at least 80% of the variance in the overall UPDRS score.
At the end of this process, the cloudUPDRS system is configured with an
individual user profile detailing the subgroup of observations identifed for inclu-
sion in the quick test. This profile is automatically communicated to the app
at the next start up so that it is reconfigured to enable the quick test feature in
its home screen (cf. Figure 2). The selected settings remain active for a period
of six months after which a new set of full tests is required due to the likelihood
of changes in motor symptoms over this time frame.
8.3. Results
To evaluate the effectiveness of this approach we employed the data set
described in Section 8.1 selecting only patients for which at least five full test
results are available. For each patient we apply the above methodology to create
a personalised quick test profile. We discover that in all cases we are able to
account for the target variance using features associated with only three or less
observations. This result is consistent across all patients examined representing
medium and progressed stages of the disease.
Figure 12 shows the results of this analysis for a typical patient from this
cohort suggesting in this case that just three observations (from which seven
features are calculated) are adequate to account for approximately 90% of the
variation. Specifically, this patient’s quick test profile consists of observations
of left leg agility, right arm rest tremor and single tapping of the left hand
which provide the adequate information to track their overall motor perfor-
mance. System logs confirm that this patient was able to complete the quick
tests consistently in less than 4 minutes over 50 times in the two months fol-
lowing the availability of their profile. Note that this patient is at an advanced
stage of PD presenting significant mobility impairments.
41
Figure 12: Predictive power of features associated with individual UPDRS observations.
9. Future Work and Conclusions
The results presented in this paper are promising but for the clinical com-
munity to accept cloudUPDRS as a standard tool for the assessment of PD, it
is necessary to validate its performance against the higher standards required
for medical research and practice. To this end, we are currently undertaking a
full clinical study of the cloudUPDRS app.3 CUSSP is a single-site, open label
study carried out at University College Hospital in London, U.K. comparing the
validity and usability of the cloudUPDRS score for home monitoring of symp-
toms and signs in PD. The primary objective is to validate in a clinical setting
the UPDRS score computed automatically by cloudUPDRS against the clini-
cally defined UPDRS score which is currently recognized as the gold standard.
Participating patients with PD are assessed in the clinic under so-called L-Dopa
challenge conditions, that is after an overnight period of no medication, and sub-
sequently after medication administration thus observing motor performance in
OFF and ON conditions. These assessments are video-recorded at a baseline
visit by an unblinded rater, and the video is further assessed by two blinded
raters, to produce three repeated scores of the clinical gold-standard UPDRS.
During the same hospital visit, the patient performs the UPDRS assessment
3CUSSP: The CloudUPDRS Smartphone Software in Parkinson’s Study cf.
https://clinicaltrials.gov/ct2/show/NCT02937324.
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in the ON and OFF conditions using the cloudUPDRS. The clinical and app
scores are then compared, first using the Bland-Altman agreement between the
score calculated by cloudUPDRS and the average clinical UPDRS rating score.
This is in the form of a mean difference and 95% confidence interval of the limit
of agreement. To assess whether the mean difference varies with UPDRS score,
we also generate the Bland-Altman plot. Second, to determine how the cloud-
UPDRS score compares to the inter-rater agreement, we also assess agreement
between different combinations of gold-standard raters. Finally, to assess the
relative validity of different elements of the cloudUPDRS score, we present their
intra-class correlation coefficients. CUSSP is expected to report its findings at
the end of 2017.
Further to the consideration of questions of clinical validation and the longer-
term improvement of treatment strategies for PD, cloudUPDRS also represents
an attempt to address the challenges created by a global aging population. In-
deed, according to the World Health Organization [67], ageing populations gen-
erate considerable economic effects, notably intensifying pressures on health-care
systems which for many of the more economically developed countries already
represent the largest area of expenditure. In the UK, the cost of caring for PD
patients exceeds 1.25 billion British pounds annually and is rapidly increasing.
In this socioeconomic situation, mobile health apps present a unique opportunity
for the provision of cost effective care at population scale. Yet, to reach their
full potential such apps must offer safety guarantees and facilitate a seamless
user experience.
To this end, cloudUPDRS is the first smartphone app to receive certification
as a medical device for the clinical assessment of Parkinson’s Disease. The design
and development of cloudUPDRS follows the structured process required to
ensure the safety guarantees required by medical devices and at the same time
support an efficient and effective patient experience that facilitates its wider
adoption. A key ingredient to achieve the latter is the introduction of two novel
features developed specifically for cloudUPDRS, supplemented by a bespoke
patient expereince design that provides structure and guidance during use at
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home. First, a tailored deep learning approach was employed to replace expert
human supervision during the administration of the common motor performance
assessment protocol for PD. In particular, in this paper an improved neural
network architecture was presented, implemented as two-stage approach where
high-performance resources are used to train the model which is subsequently
embedded in the cloudUPDRS app operation on the mobile phone to provide
interactive oversight. Second, recognizing the need for frequent assessments
especially in the period leading to a clinical appointment, a personalised quick
test was developed lasting less than 5 minutes per application to accurately trace
overall motor performance while considerably improving patient compliance. In
our experiments both approaches performed reliably and produce promising
results. We anticipate both techniques to be useful for a wider class of mobile
health-care apps with similar requirements. Further experimentation with a
larger patient population outside the PD context is of course necessary to fully
assess the wider potential of the techniques presented in this paper.
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